• Implement drug testing policies and procedures in accordance with SAMHSA Guidelines and DOT Regulations.
• Compare and contrast between the different toxicology specimens, their benefits and limitations.
• Describe the role of an MRO in a forensic drug testing program.
• Review the latest requirements for the MRO review of confirmed laboratory results, split specimen testing, invalid, adulterated and substituted results.
• Apply the information presented from this presentation to support your clients and help ensure public safety in and beyond the workplace.

Anthony Dekker, DO

Dr. Ferguson is the Medical Director of Vault Health (Formerly FSSolutions) Recovery Management Solutions. He is a Diplomate of the American Board of Addiction Medicine (ABAM), a Distinguished Fellow of the American Society of Addiction Medicine (ASAM), and a Medical Review Officer (MRO) certified by the Medical Review Officer Certification Council. He directed the ASAM Comprehensive MRO Training Course from 2003 until 2013 and currently teaches MRO Training through the American Osteopathic College of Occupational and Preventive Medicine (AOCOPM) and the American College of Occupational and Environmental Medicine (ACOEM). He is Chairman of the Board of Directors of the Medical Review Officer Certification Council (MROCC), the author of “The MRO Team Manual,” co-author of the MRO chapters of the ”Principles of Addiction Medicine” and the “Handbook of Workplace Drug Testing”. He is a former member of the SAMHSA Drug Testing Advisory Board (DTAB) and still consults for the Substance Abuse and Mental Health Services Administration (SAMHSA) Division of Workplace Programs (DWP). He was instrumental in the development of the National MRO Database Project and served as a member of the industry-based Oral Fluid Advisory Board.

Barry Sample, Ph.D., is a consultant and expert in forensic and analytical toxicology, anti-doping, and workforce drug testing.

Dr. Sample began his career in laboratory medicine at Indiana University in 1977. After earning his doctoral degree in 1985, he joined the faculty in the Department of Pathology at I.U. where he was responsible for the day-to-day operation of the SportsMedicine Drug Identification laboratory. During his tenure, the laboratory was accredited by the International Olympic Committee and conducted drug testing for the 1987 Pan American Games.

Dr. Sample worked for Quest Diagnostics for more than 30 years, starting in 1991 as laboratory director. Under his direction, the Atlanta laboratory, which was accredited by the International Olympic Committee, provided the doping control services for the 1996 Centennial Olympic Games. In 2000, Dr. Sample transitioned to leading Science and Technology initiatives where he was responsible for the production and introduction of new products and services through new tests, informatics, and technology development. In early 2022, Dr. Sample retired and started consulting to laboratories,
device manufacturers, and industry organizations as well as providing expert testimony services.

Currently, Dr. Sample is extensively involved in numerous professional organizations. He is a Regional Commissioner and an inspector for the College of American Pathologists (CAP) Forensic Drug Testing (FDT) laboratory accreditation program, serves as a member of the Tennis (ITF/ITIA) Anti-Doping Program Review Board and the National Basketball Association (NBA) Prohibited Substances Committee and served nine years on the Board of Directors and is past-President of the Substance Abuse Program Administrators Association. He has served as a consultant to the CAP Toxicology Resource Committee, as a member of the U.S. Anti-Doping Agency Review Board, and for two, four-year terms as a member of the DHHS Drug Testing Advisory Board. He is a lecturer and has co-authored numerous presentations and publications dealing with drug analysis, athletic drug testing, and toxicology. Dr. Sample received his bachelor’s degree in chemistry and his doctorate in pharmacology from Indiana University.